Skip to main content
< Back to news
Alfons Nonell-Canals, CEO of Mind the Byte, during the presentation of the SaaS platform to Massachusetts BioITcommunity.
 04.05.2016

Mind the Byte launches six new software to accelerate drug discovery

In line with the ground-breaking pay-per-use philosophy, Mind the Byte has launched six new programs for computational drug design on their SaaS platform (Software as a Service), which the company has been marketing since 2011. The new software expands the services currently on offer and helps cut drug-development time and costs up to 30% for companies and researchers. The products were launched at prices that adapt to the needs of each user.

 

The new SaaS programs are: Chaac (D ligand-based virtual screening), Kizin (2D ligand-based compound selection), Ik (3D virtual screening), Ixtab(management of chemical libraries), Kin (blind-docking technology for predicting protein-ligand interactions) and Itzamma (identify active compounds for a target using docking technology). All them are designed exclusively by the Mind the Byte team of engineers, bioinformatics and computational chemists at the Barcelona Science Park (PCB). ckholm and now the aim is to continue promoting the SaaS in mature pharmaceutical and biotechnology markets like the United States, Denmark, Germany and Japan, in addition to Spain. Just a few days ago, in fact, the Bioga cluster invited Mind the Byte CEO Alfons Nonell-Canals to explain to a group of Galician biotechnicians how they could benefit from bioinformatics, not only in the health arena but also in agrifood, which is an important part of the economy in Galicia. 

“When we created the SaaS platform, we had a clear aim: to break through the most important technological and economic barriers of computational design and help reduce time-to-market for new drugs, thus speeding up the arrival of innovative treatments for unmet medical needs,” says Nonell-Canals.  

To achieve it, Mind the Byte is applying mathematical models and algorithms using machine learning (artificial intelligence) and big data.

In addition to the SaaS platform, Mind the Byte also offers personalised computational drug-discovery services for biotech and pharmaceutical companies and research centres around the world.